Stock Update (NYSE:AGN): Allergan Announces FDA Approval of ACZONE® (dapsone) Gel, 7.5% for Treatment of Acne Vulgaris

[PR Newswire] – DUBLIN, Feb. 25, 2016 /PRNewswire/ — Allergan plc ( NYSE:AGN ), a leading global pharmaceutical company, today announced that the Company has received approval from the U.S. Food and Drug Administration … Read more on this. Allergan plc (AGN) , valued at $116.82B, opened at $285.42. Looking at today’s trading action, the company’s one day range from $285.03 to $297.18 and has traded between $237.50 and $340.34 over the past year. AGN shares are currently priced at 19.29x this year’s forecasted earnings, which makes them relatively expensive compared to the industry ’s -4.37x forward p/e ratio. And for dividend hunters, the company pays shareholders $0.20 per share annually in dividends, yielding 0.10%. Consensus earnings for the current quarter by the 11 sell-side analysts covering the stock is an estimate of $3.20 per share, which would be $1.10 worse than the year-ago quarter and a $0.45 sequential decrease. What we find to be interesting is that the full-year EPS estimate of $14.76 is a $1.33 improvement when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $4.06 Billion. If realized, that would be a 3.33% decrease over the year-ago quarter. More recently, Wells Fargo Initiated AGN at Outperform (Feb 19, 2016). Previously, Mizuho Initiated AGN at to Buy. When considering if perhaps the stock is under or overvalued, the average price target is $357.93, which is 25.40% above where the stock opened this morning. See more in (NYSE:AGN) Similar Articles: Company Update: Allergan Inc (NYSE:AGN) – Allergan to Present at the RBC Capital Markets Healthcare Conference Stock Update: Allergan Inc (NYSE:AGN) – Allergan to Report Fourth Quarter and Full-Year 2015 Earnings and Host Conference Call and Webcast Stock Update: Allergan Inc (NYSE:AGN) – Allergan and Pfizer to Present at 34th Annual J.P. Morgan Healthcare Conference